Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
188 hedge funds and large institutions have $1.6B invested in Intercept Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 56 increasing their positions, 71 reducing their positions, and 49 closing their positions.
0% less call options, than puts
Call options by funds: $79.6M | Put options by funds: $79.9M
13% less funds holding
Funds holding: 215 → 188 (-27)
21% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 71
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
47% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 49
50% less capital invested
Capital invested by funds: $3.2B → $1.6B (-$1.6B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$26.5M |
| 2 |
Renaissance Technologies
New York
|
+$19.2M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$15.3M |
| 4 |
Barclays
London,
United Kingdom
|
+$15.1M |
| 5 |
Two Sigma Advisers
New York
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.8M |
| 2 |
Jennison Associates
New York
|
-$20.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$20.1M |
| 4 |
SM
Senvest Management
New York
|
-$12.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$12.4M |
ICPT Hedge Fund Activity: Q1 2020 in Review
188 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2020, worth a combined $1.6B — down 50% from $3.2B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of ICPT and 26 opened new positions — a net loss of 23 holders — while 71 trimmed existing stakes and 56 added.
The largest buyer was Sarissa Capital Management, adding an estimated $26.5M. The largest seller was Wellington Management Group, exiting entirely with an estimated $33.8M sold.
- 188 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2020, down from 215 in Q4 2019.
- Funds reported $1.6B of Intercept Pharmaceuticals, Inc. stock for Q1 2020, down 50% quarter-over-quarter.
- 26 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2020 and 49 closed out, a net change of -23 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2020 was Sarissa Capital Management, an estimated $26.5M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2020 was Wellington Management Group, an estimated $33.8M sold.
Based on aggregated 13F filings for Q1 2020.